Stay aware of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking the complex interactions between biological processes and the myriad states of the human mind. Ranked No. 7 among the nation's psychiatry departments for National Institute of Health funding, Mount Sinai is unrelenting in its commitment to advancing life-changing treatment. The Department is a vibrant community of psychiatric clinicians, researchers, educators, and trainees, and is a national model for groundbreaking clinical research in neuropsychiatry. Our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction, to major depression, autism, and schizophrenia.
Stay aware of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking the complex interactions between biological processes and the myriad states of the human mind. Ranked No. 7 among the nation's psychiatry departments for National Institute of Health funding, Mount Sinai is unrelenting in its commitment to advancing life-changing treatment. The Department is a vibrant community of psychiatric clinicians, researchers, educators, and trainees, and is a national model for groundbreaking clinical research in neuropsychiatry. Our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction, to major depression, autism, and schizophrenia.
The year 2022 was a productive and prolific one for our department. We launched the Center for Disease Neurogenomics—one of the few in the world with access to brain tissue and population-level datasets.
This study is the first to examine in utero exposure to stimulants and long term child outcomes. Researchers examined almost 900 children who were exposed to ADHD during the mothers’ pregnancy and 1270 children who were not.
Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism.
While people who are pregnant can easily learn how to safeguard their physical health and that of their babies, information about mental health concerns is scarcer.
Yasmin Hurd, PhD, and Helen Mayberg, MD, have paved new paths in addiction and depression research by opening new lines of inquiry into treatment approaches: the therapeutic potential of CBD, and a specific target for deep brain stimulation.
Rachel Yehuda, PhD, is exploring whether psychedelics can be a useful treatment for post-traumatic stress disorder (PTSD). Her journey began with a study on 3,4-methylenedioxy-methamphetamine (MDMA) in veterans and is expanding to investigate psilocybin.
The Jeff and Lisa Blau Adolescent Consultation Center for Resilience and Treatment is studying 10 rare genetic mutations that are implicated in schizophrenia.
Past social trauma is encoded by a population of stress/threat-responsive brain cells that become hyperactivated during subsequent interaction with non-threatening social targets.
Researchers from the Icahn School of Medicine at Mount Sinai have learned that the way the brain processes the complex emotion of regret may be linked to an individual’s ability to cope with stress, and altered in psychiatric disorders like depression.
Stem cell-derived neurons from combat veterans with post-traumatic stress disorder (PTSD) react differently to a stress hormone than those from veterans without PTSD.
White matter in the brain that was previously implicated in animal studies has now been suggested to be specifically impaired in the brains of people with addiction to cocaine or heroin.
New data from the longitudinal Stress in Pregnancy Study have identified earlier onset and higher rates of developmental psychopathology among children whose mothers were pregnant during Superstorm Sandy.
Mount Sinai’s Psychosis Risk Program provides patients and families with education and CBT early on, as well as the opportunity to participate in research trials
Each day, approximately 17 veterans die by suicide, according to the 2020 National Veteran Suicide Prevention Annual Report. Of those lives lost, 68% die from a self-inflicted firearm injury.
At the Aspen Ideas Festival, a distinguished panel of researchers and entrepreneurs, including Mount Sinai’s Rachel Yehuda, PhD, discuss pioneering approaches to psychedelics for mental health care
In the East Harlem neighborhood of New York City, residents without access to health insurance are receiving free outpatient mental health care, thanks to an innovative project at the Icahn School of Medicine at Mount Sinai.
Dr. Khachadourian is helping to paint a more complete picture of the environmental exposures that affect pregnant people and their developing children.
In 2021, two professors from the Department of Psychiatry received Mount Sinai's highest honors in academic medicine: Rita Goldstein, PhD, and Rachel Yehuda, PhD.
For the first time, stem cell-derived organoid models are allowing scientists to study the cellular development and intercellular interactions among microglia and other cell types within a 3D human brain microenvironment.
Mount Sinai's Center for Stress, Resilience and Personal Growth was created to help frontline health workers cope with the psychosocial trauma of the COVID-19 pandemic.
Mount Sinai's Department of Psychiatry provides residents and fellows with the resources and support they need to turn patient experience into valuable research so they can become fluent in both science and medicine.
The Department of Psychiatry is training students, residents, and fellows on the issues of social justice and diversity and working toward the elimination of race-based discrepancies in the diagnosis and treatment of patients.
The unique pairing of the Nash Family Center for Advanced Circuit Therapeutics and the Center for Computational Psychiatry is generating some of the nation's most advanced research into the brain.
An estimated three-quarters of all psychiatric disorders debut prior to or during adolescence. To address this, in October 2021, Mount Sinai established the Jeff and Lisa Blau Adolescent Consultation Center for Resilience and Treatment.
In addition to launching three centers, we were ranked No. 7 in National Institutes of Health (NIH) funding for psychiatry, published more than 850 papers, completed more than 800,000 outpatient visits, and received $49 million in active grants.
Eric Nestler, MD, PhD, moderates 20-minute talks from Yasmin Hurd, PhD; Xiaosi Gu, PhD; Kara Bagot, MD; and Timothy Brennan, MD, MPH. You'll hear about what we know, what we're learning, and how we're implementing what we learn about substance abuse
Scientists trained as physicians, like Dr. Sweis, are in a unique position to understand and enhance the links between preclinical research and clinical applications in humans to advance patient treatments. Read about his path, and where he plans to go next.
Mount Sinai has been on the forefront of trauma, stress, depression, and resilience research for decades. This virtual symposium covers the latest: what we know, and what we are learning that can equip us in addressing the pandemic’s psychological ...
Listen or read the transcript of this informative podcast with Rachel Yehuda, PhD, on the potential of MDMA to treat patients with post-traumatic stress disorder
New research center will focus on studying MDMA, psilocybin, and other psychedelic compounds to treat post-traumatic stress disorder, depression, and other psychological conditions
Repeated intravenous ketamine infusions significantly reduce symptom severity in individuals with post-traumatic stress disorder and the improvement is rapid and maintained for several weeks afterwards, according to a study conducted by ...
As a response to COVID-19, we created a Center for Stress, Resilience, and Personal Growth to provide mental health services to our staff, faculty, students, and trainees. Services include individualized assessments, planning, and coaching; ...
Listen as Mount Sinai neuroscientists discuss ketamine, cannabis, and ecstasy as potential treatments for treatment-resistant depression, opioid addiction, and post-traumatic stress disorder
Health care workers will likely be facing significant mental health consequences due to their involvement with COVID-19. Check out the top five things to know about providing psychiatric care to these health care workers during and after the pandemic.
Veerle Bergink, MD, PhD, discusses mental health during pregnancy and the postpartum period during COVID-19, including potential long-term effects on the child’s brain.
Cheryl Corcoran, MD, discusses how speech and language markers can be used to track physiology and psychiatric sequelae related to COVID-19 course together with other variables and biomarkers.
New York City is an epicenter of COVID-19 pandemic in the United States, and the Mount Sinai Health System has spearheaded an array of clinical and organizational innovations to mitigate the crisis.
Laura Huckins, PhD, Assistant Professor of Psychiatry, and Genetics and Genomic Sciences, discusses a new app-based survey gathering data on New York City residents and their COVID-19-related symptoms in order to better understand transmission ...
Craig Katz, MD, Director of Mount Sinai’s Program in Global Mental Health, breaks down how to deliver psychological first aid in a disaster setting in order to prevent post-disaster psychopathology.
In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and Drug Administration (FDA) to treat patients with treatment-resistant depression (TRD). James Murrough, MD, ...
MDMA, the psychoactive drug sometimes known as ecstasy, is poised to become a powerful tool in the treatment of PTSD. In 2017, the U.S. Food and Drug Administration (FDA) designated MDMA-assisted psychotherapy as a breakthrough therapy.
“In five years, we expect to have a range of new treatments available targeting people with different forms of depression that work effectively, specifically for them.” –Eric Nestler, MD, PhD
